SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)

• SYFOVRE reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension study
• Well-demonstrated safety profile consistent with previously reported clinical data
• Approximately 92% of patients enrolled in GALE completed the first year of the study, demonstrating robust long-term compliance
• Data were presented during an oral presentation at the American Academy of Ophthalmology (AAO) Annual Meeting

A Media Snippet accompanying this announcement is available by clicking on this link.

WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 3 years of continuous treatment with SYFOVRE® (pegcetacoplan injection), the first-ever FDA-approved treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The data were reported during an oral presentation at the American Academy of Ophthalmology (AAO) Annual Meeting.

“We are continuing to see increasing SYFOVRE treatment effects year-over-year and a more than 40% reduction in nonsubfoveal lesion growth in the third year,” said Caroline Baumal, M.D., chief medical officer, Apellis. “Additionally, SYFOVRE is the only treatment that offers dosing beyond 12 months, and these results demonstrate the importance of early and continuous treatment over time.”  

SYFOVRE continued to demonstrate increasing treatment effects over time. In Year 3, SYFOVRE (all p-values nominal):

• Reduced GA lesion growth with both monthly (35%; p